Table 2.
Mean proportions of patient-important outcomes per trial, stratified by trial characteristics
| Outcome | Trial characteristic; %* | ||||
|---|---|---|---|---|---|
| All trials | Superiority trials | Noninferiority trials | Full or partial industry funding | Nonindustry funding | |
| No. of trials | 350 | 335 | 15 | 70 | 83 |
| Any patient-important outcome | 60 | 60 | 67 | 58 | 56 |
| Mortality/survival | 2 | 2 | 3 | 2 | 2 |
| Pain | 7 | 7 | 6 | 7 | 6 |
| Function | 7 | 7 | 10 | 10 | 6 |
| Quality of life | 4 | 3 | 8 | 5 | 6 |
| Morbid events/symptoms | 29 | 28 | 30 | 25 | 25 |
| Patient satisfaction | 2 | 2 | 0 | 0 | 3 |
| Intervention outcomes | 10 | 10 | 10 | 10 | 9 |
| Surrogate outcomes | 29 | 29 | 26 | 32 | 31 |
| Laboratory outcomes | 10 | 10 | 7 | 8 | 12 |
*
Unless indicated otherwise.